Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us
Anlotinib

Sourced directly from the authorized manufacturer network to ensure authenticity and quality.

Ready to proceed? Order Anlotinib on our secure patient portal to submit your prescription, upload documents and track your approval status.

Anlotinib

Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.

Medicine Name: Anlotinib
Generic Name (API): Anlotinib Hydrochloride
Dosage Form & Strength: 12 mg, 10 mg, 8 mg, 6 mg
Route: Oral
Drug Class: Multi-target tyrosine kinase inhibitor (VEGFR, FGFR, PDGFR, c-Kit, RET)

Manufacturer / Innovator:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Regulatory Approval:

  • NMPA (China)
Family enjoying life with Named Patient Program access

Your Trustworthy Partner For Named Patient Program

  • your trusted partner for named patient program

    Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.

  • 100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

    100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.

  • Medicines sourced from authorized manufacturers with full batch traceability

    Medicines sourced from authorized manufacturers with full batch traceability.

  • EU-GDP Compliant Warehousing for secure, quality-controlled global distribution.

    EU-GDP compliant warehousing for secure, quality-controlled global distribution.

  • Temperature-Controlled Logistics for Safe and Timely Delivery

    Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.

GDP Compliant View Certificate
Licensed Wholesale distributor View Certificate

What Is Anlotinib Used For?

Anlotinib is a once-a-day capsule used for several kinds of advanced cancer, most often lung cancer and soft tissue sarcoma. It is made in China by Chia Tai Tianqing Pharmaceutical Group (part of Sino Biopharm) under the brand name 福可维 (Focus V®), and was co-developed with Advenchen Laboratories. China's National Medical Products Administration (NMPA) first approved it in May 2018, for lung cancer that had kept growing after chemotherapy.

The current Chinese label (updated 2026) lists these uses in adults:

  • Non-small cell lung cancer (NSCLC): locally advanced or metastatic disease that has progressed after at least two lines of chemotherapy. People with an EGFR mutation or ALK-positive cancer must first have had the standard targeted treatment. It is also used, after initial chemotherapy, with benmelstobart as first-line treatment for advanced squamous NSCLC.
  • Small cell lung cancer: on its own after at least two chemotherapy regimens, or with benmelstobart and chemotherapy as first-line treatment for extensive-stage disease.
  • Soft tissue sarcoma: on its own for alveolar soft part sarcoma, clear cell sarcoma and other advanced sarcomas that progressed after anthracycline chemotherapy; with epirubicin as first-line treatment; and with benmelstobart for alveolar soft part sarcoma (a conditional approval).
  • Differentiated thyroid cancer: progressive, locally advanced or metastatic cancer that no longer responds to radioactive iodine.
  • Endometrial, kidney and liver cancer: in combination with an antibody made by the same group (benmelstobart for endometrial and kidney cancer, penpulimab for liver cancer). The endometrial use is a conditional approval.

It is a prescription cancer medicine and should only be started and managed by an oncologist.

How It Works

Tumours need a steady blood supply to grow, and they send out signals to build new vessels. This capsule is a multi-target tyrosine kinase inhibitor: it blocks the VEGFR1–3, FGFR1–4 and PDGFR α/β receptors that drive that vessel growth, and also c-Kit and RET, which some cancer cells use to multiply. Starving the tumour of new vessels slows it down.

What the Trial Showed

Its first approval rested on ALTER0303, a phase 3 study in China of 437 people with advanced NSCLC that had come back after two or more lines of chemotherapy. Participants were randomised two to one to the capsule or a placebo. Median overall survival was 9.46 months against 6.37 months (hazard ratio 0.70), and the time before the cancer grew again rose from 1.40 to 5.37 months. About 81% of treated patients had their disease shrink or stay stable, compared with 37% on placebo.

Recommended Dosage

  • Usual dose: 12 mg by mouth once a day, before breakfast
  • Schedule: two weeks on, then one week off, so each cycle lasts 21 days
  • Lower starting dose: 10 mg for first-line liver cancer (with penpulimab) and first-line squamous NSCLC
  • Missed dose: if the next dose is less than 12 hours away, skip it and carry on as normal
  • Dose steps: if side effects are hard to manage, the dose drops to 10 mg and then 8 mg (or 8 mg and then 6 mg from a 10 mg start); if the lowest step is still not tolerated, treatment stops

Your oncologist decides which combination, if any, is right for you and how long treatment continues.

This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.

Warnings and Precautions

Who should not take it: people allergic to any ingredient, those with central squamous lung cancer that has cavities or a high risk of major coughing up of blood, people with severe liver or kidney impairment, and women who are pregnant or breastfeeding.

  • Bleeding: the label calls this its most important side effect. In the pooled single-agent studies (1,905 patients), 29.7% had some bleeding and 1.9% had grade 3 or worse. Tell your doctor at once about coughing up blood, black stools or unusual bruising.
  • High blood pressure: the most common side effect (57.2%; 15.3% grade 3 or higher). Blood pressure is checked every day for the first six weeks, then two or three times a week.
  • Hand-foot skin reaction: redness, peeling or blisters on palms and soles in 42.4% (4.7% severe). Moisturisers and avoiding pressure or heat on the feet help.
  • Urine protein and kidneys: proteinuria in 36.8%; urine is tested every six to eight weeks.
  • Liver and thyroid: raised liver tests in 37.3% and an underactive thyroid in 21.1%, so blood tests are repeated during treatment.
  • Heart rhythm: it can lengthen the QT interval; an ECG is advised every six to eight weeks.
  • Surgery and wounds: it can slow healing, so it is paused before major surgery.
  • Pregnancy: women should use reliable contraception during treatment and for 6 months afterwards; men for 3 months afterwards.

Other effects: tiredness, diarrhoea, poor appetite, raised blood fats, mouth sores and, rarely, a brain swelling syndrome called RPLS (headache, fits, vision changes). Strong CYP3A4 or CYP1A2 inhibitors and inducers can change blood levels, and grapefruit should be avoided. Safety in children under 18 has not been established.

How to Access Anlotinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Anlotinib to India?

The capsules can be brought in only in the patient's own name, by the patient or a government hospital, following India's rules for importing unapproved medicines. Please keep ready:

  • A valid prescription from a medical oncologist
  • Biopsy and imaging reports confirming the cancer type and stage, plus a summary of earlier treatment (for lung cancer, the chemotherapy lines and any EGFR/ALK test result)
  • Patient ID proof (issued by the Government of India)

How is the order confirmed?

Only after we have checked the prescription and, if required, the import permit.

Is Anlotinib available in India?

No. It is approved in China only. CDSCO has not approved it, so it is not stocked by Indian pharmacies. The US FDA has not approved it, and a European application (under the name catequentinib) was withdrawn in October 2026 after a negative opinion.

A legal way to obtain it is the Named Patient Program (NPP), which lets one named patient import a medicine that is not registered in India against a doctor's prescription. We also handle other China-approved cancer tablets that block blood vessel growth, such as vorolanib for kidney cancer and famitinib.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for storage in the sealed pack, away from light and moisture, at no more than 25°C, so the boxes travel unopened under temperature-controlled shipping. Since one cycle uses 14 capsules, we usually plan supply for one or more full cycles at a time. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Patients across India can access this medicine through regulated import pathways, with delivery to the patient or treating hospital on a valid oncologist's prescription.

Delhi

Large cancer hospitals in Delhi treat lung cancer and sarcoma patients from across the north, and dispatch from New Delhi keeps transit time short.

Mumbai

Oncologists in Mumbai can send the prescription and scan reports, and the capsules are delivered to the patient or the hospital pharmacy.

Bangalore

Patients in Bangalore receive a written quote first, and nothing is ordered until the family agrees.

Chennai

For patients treated in Chennai, we time each shipment so the next 21-day cycle can start without a break.

Hyderabad

Thoracic oncology teams in Hyderabad can request the capsules for a named patient after earlier chemotherapy has stopped working.

Kolkata

Families in Kolkata and the north-east receive tracking updates from dispatch until the box is in their hands.

Pune

Sarcoma and lung cancer patients in Pune can use the same documented import route as in the metros.

Ahmedabad

Doctors in Ahmedabad can share the treatment history with us, and we confirm what paperwork is still needed.

Vellore

Patients treated at hospitals in Vellore can have the supply sent to the hospital so it fits in with their clinic reviews.

Chandigarh

We deliver to patients and cancer centres across Punjab, Haryana and Himachal Pradesh through Chandigarh.

Lucknow

Patients across Uttar Pradesh can receive the medicine at home or at their treating hospital in Lucknow.

Kochi

Patients in Kerala can have each cycle's capsules delivered to Kochi and nearby towns.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.

Author Details

Nitin Goswami

Written By

Nitin Goswami

Deputy Manager – Content & Social Media, Ikris Pharma Network

Sources: NMPA • CDSCO

Dr. Chirag C Shah

Medically Reviewed By

Dr. Chirag C Shah

MBBS

Last Updated: 18 November 2026

More Oncology Medicines

TRUSTED BY HEALTHCARE PROFESSIONALS & HOSPITALS

Need Help
Accessing Medicines?

Our specialists are here to guide you through every step of the medicine access process.

Let's us help!

Send us a message

Read how to access medicines

Read More arrow icon

Frequently Asked
Questions

Read More
Meet the NPP Assistant: ask us anything about NPP